molecules-logo

Journal Browser

Journal Browser

Molecules for Biotechnologies II

A special issue of Molecules (ISSN 1420-3049).

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 12901

Special Issue Editors

Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Via Sergio Pansini 5, 80131 Napoli, Italy
Interests: nucleoside; nucleotide and nucleic acid analogues; spectrometric and spectroscopic analysis
Special Issues, Collections and Topics in MDPI journals
Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy
Interests: nucleic acid chemistry and biology; DNA quadruplexes formed by telomers, aptamers, and synthetic G-rich oligonucleotides; chemical-physical characterization of soft interfaces; hybrid interfaces; therapeutics; diagnostics
Special Issues, Collections and Topics in MDPI journals
Department of Biotechnology and Biosciences, University of Milano-Bicocca, I-20126 Milan, Italy
Interests: biomaterials; bioconjugation; biopolymers; carbohydrate chemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In this extraordinary period, in which each of us has been doing our best to overcome the difficulties of the moment, and considering the attention that the biotechnology field has been receiving, we would like to announce a new Special Issue of Molecules entitled “Molecules for Biotechnologies II”. This Special Issue welcomes original papers and comprehensive reviews focused on, but not limited to, the design, synthesis, and biochemical characterization of molecules involved in biotechnological applications, such as the development of novel approaches for molecular biosensing in diagnostics and the obtainment of new biomaterials and drug delivery systems. Please refer to the list of keywords for further details.

Prof. Dr. Giorgia Oliviero
Prof. Dr. Nicola Borbone
Dr. Laura Cipolla
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • synthesis
  • oligonucleotides and analogues
  • aptamers
  • biosensors
  • biocatalysis
  • drug delivery
  • quorum sensing
  • medicinal chemistry
  • peptides
  • biomaterials

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1225 KiB  
Review
An Update of Nucleic Acids Aptamers Theranostic Integration with CRISPR/Cas Technology
by Mina Roueinfar, Hayley N. Templeton, Julietta A. Sheng and Ka Lok Hong
Molecules 2022, 27(3), 1114; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27031114 - 07 Feb 2022
Cited by 8 | Viewed by 4330
Abstract
The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system is best known for its role in genomic editing. It has also demonstrated great potential in nucleic acid biosensing. However, the specificity limitation in CRISPR/Cas has created a hurdle for its advancement. More recently, [...] Read more.
The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system is best known for its role in genomic editing. It has also demonstrated great potential in nucleic acid biosensing. However, the specificity limitation in CRISPR/Cas has created a hurdle for its advancement. More recently, nucleic acid aptamers known for their high affinity and specificity properties for their targets have been integrated into CRISPR/Cas systems. This review article gives a brief overview of the aptamer and CRISPR/Cas technology and provides an updated summary and discussion on how the two distinctive nucleic acid technologies are being integrated into modern diagnostic and therapeutic applications Full article
(This article belongs to the Special Issue Molecules for Biotechnologies II)
Show Figures

Figure 1

17 pages, 1344 KiB  
Review
Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
by Nicola Borbone, Gennaro Piccialli, Giovanni Nicola Roviello and Giorgia Oliviero
Molecules 2021, 26(4), 986; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules26040986 - 13 Feb 2021
Cited by 60 | Viewed by 7742
Abstract
Coronaviruses (CoVs) are positive-sense RNA enveloped viruses, members of the family Coronaviridae, that cause infections in a broad range of mammals including humans. Several CoV species lead to mild upper respiratory infections typically associated with common colds. However, three human CoV (HCoV) species: [...] Read more.
Coronaviruses (CoVs) are positive-sense RNA enveloped viruses, members of the family Coronaviridae, that cause infections in a broad range of mammals including humans. Several CoV species lead to mild upper respiratory infections typically associated with common colds. However, three human CoV (HCoV) species: Severe Acute Respiratory Syndrome (SARS)-CoV-1, Middle East Respiratory Syndrome (MERS)-CoV, and SARS-CoV-2, are responsible for severe respiratory diseases at the origin of two recent epidemics (SARS and MERS), and of the current COronaVIrus Disease 19 (COVID-19), respectively. The easily transmissible SARS-CoV-2, emerging at the end of 2019 in China, spread rapidly worldwide, leading the World Health Organization (WHO) to declare COVID-19 a pandemic. While the world waits for mass vaccination, there is an urgent need for effective drugs as short-term weapons to combat the SARS-CoV-2 infection. In this context, the drug repurposing approach is a strategy able to guarantee positive results rapidly. In this regard, it is well known that several nucleoside-mimicking analogs and nucleoside precursors may inhibit the growth of viruses providing effective therapies for several viral diseases, including HCoV infections. Therefore, this review will focus on synthetic nucleosides and nucleoside precursors active against different HCoV species, paying great attention to SARS-CoV-2. This work covers progress made in anti-CoV therapy with nucleoside derivatives and provides insight into their main mechanisms of action. Full article
(This article belongs to the Special Issue Molecules for Biotechnologies II)
Show Figures

Figure 1

Back to TopTop